BI 894416
Alternative Names: BI-894416Latest Information Update: 28 Nov 2023
At a glance
- Originator Boehringer Ingelheim
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Japan (PO)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Asthma(In volunteers) in United Kingdom (PO, Capsule)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Asthma(In volunteers) in United Kingdom (PO, Tablet)